Barley fiber changed liver and fat-tissue genes for fat handling and improved health markers in obese mice

Quick Summary

β-glucan is a soluble fiber in barley. It can be fermented by gut microbes into short-chain fatty acids (SCFAs), which may influence how the body handles fats and sugars. 

Original Paper

Copied!

This Study Summary was published on January 16, 2026.

    Written by:
    1. Beta Glucan PhD Team,

      Beta Glucan PhD Team

      Beta Glucan PhD Team

    Fact-checked by:

      We rely on peer-reviewed scientific research to determine what’s truly effective. Our goal is to provide clear, unbiased information to help you make better health decisions.

      We use AI tools to help summarize studies, and every piece of content is reviewed and approved by qualified experts, ensuring it’s accurate and trustworthy.

      Beta Glucan is fully independent — we don’t sell products, run ads, or accept sponsorships. Our only focus is delivering reliable, science-backed insights.

      Key study details

      Objective
      Determine whether β-glucan–rich barley flour alters expression of genes involved in glucose and lipid metabolism across ileum, liver, and adipose tissues in high-fat diet (HFD)–induced obese male mice and explore relationships with cecal short-chain fatty acids (SCFAs). 

      Methods

      • Male C57BL/6J mice, purchased at 4 weeks old, acclimatized 1 week, then randomized by body weight into 2 diet groups (n=10/group). Mice were provided with diets for 92 days.
      • High-fat diet prepared by adding lard to AIN-93G (fat energy ratio 50%). Both diets formulated to 5% total dietary fiber: Control used cellulose; BF diet used β-glucan–rich barley flour (“Beau Fiber”, BF). Diet β-glucan content: 0.0% (Control) vs 2.4% (BF).
      • C57BL/6J male mice were fed an HFD supplemented with high-β-glucan barley flour for 92 days. 
      • Outcomes: 
        • Metabolic syndrome markers: organ/fat weights, liver lipids, serum lipids/hormones, glucose handling
        • Transcriptomic profiling used DNA microarrays with qPCR validation in ileum, liver, and adipose (fat) tissue
        • Cecal short chain fatty acids (SCFAs) were quantified by GC/MS

      Results

      • Metabolic syndrome markers: 
        • BF group had lower liver and fat weights vs control. Epididymal fat was not significant.
        • BF had lower liver cholesterol and triglyceride, serum TC, LDL-C, and leptin and higher serum TG vs control. HDL, NEFA, and insulin were not significant.
        • Blood glucose was lower in BF at 15- and 60-minute timepoints, other timepoints not signifcant.
      • SCFA associations: 
        • In liver, several SCFAs showed negative correlations with mRNA levels for lipid synthesis/degradation pathways; similar SCFA–transcript relationships were reported for adipose tissue. 
        • The authors infer that SCFAs are associated with gene-expression shifts influencing lipid accumulation.

      Our take

      Interpretation
      In this HFD-obesity model, β-glucan–rich barley flour primarily modulated lipid metabolic gene programs compared to glucose-associated genes, coinciding with improvements in metabolic syndrome markers. The pattern of inverse SCFA–lipid-gene correlations support a gut-derived metabolite link to hepatic/adipose lipid handling, although causality is not established. 

      Mechanisms and pathways 

      Findings point toward down-regulation of sterol/lipid biosynthetic pathways in liver and adipose with SCFA-linked associations as glucose-metabolism transcripts were unchanged in those tissues. Proposed impact: SCFA-associated transcriptional shifts reduce lipid accumulation. 

      Dosages and adverse reactions
      Amount of beta-glucan in the control and experimental diets were 0 and 2.4% respectively.

      Quality of study 

      Strengths: tissue-level transcriptomics with qPCR confirmation, SCFA quantification by GC/MS, and a 92-day intervention in a disease-relevant model.

       Limitations: sample size and detailed statistics not fully described; mechanistic links are associated; and findings are preclinical. 

      Implications
      Dietary β-glucan–rich barley may shift hepatic and adipose lipid-metabolism programs in obesity toward lower sterol/lipid synthesis, potentially via SCFA-associated pathways. Translation to humans, and definition of dose, safety, and clinical endpoints requires controlled clinical studies.

      This summary is based on peer-reviewed scientific research. We use AI tools to help condense complex studies, but all content is reviewed and approved by qualified experts before publication.

      Citation

      Copied!

      Original Paper

      Stay up to date with the latest research

      Become an Beta Glucan Insider to stay on top of the latest nutrition research, supplement myths, and more